Monitored Supplementation of Vitamin D in Preterm Infants: A Randomized Controlled Trial

Appropriate supplementation of vitamin D can affect infections, allergy, and mental and behavioral development. This study aimed to assess the effectiveness of monitored vitamin D supplementation in a population of preterm infants. 109 preterm infants (24 0/7-32 6/7 weeks of gestation) were randomized to receive 500 IU vitamin D standard therapy (n = 55; approximately 800-1000 IU from combined sources) or monitored therapy (n = 54; with an option of dose modification). 25-hydroxyvitamin D [25(OH)D] concentrations were measured at birth, 4 weeks of age, and 35, 40, and 52 & PLUSMN; 2 weeks of post-conceptional age (PCA). Vitamin D supplementation was discontinued in 23% of infants subjected to standard treatment due to increased potentially toxic 25(OH)D concentrations (> 90 ng/mL) at 40 weeks of PCA. A significantly higher infants' percentage in the monitored group had safe vitamin D levels (20-80 ng/mL) at 52 weeks of PCA (p = 0.017). We observed increased vitamin D levels and abnormal ultrasound findings in five infants. Biochemical markers of vitamin D toxicity were observed in two patients at 52 weeks of PCA in the control group. Inadequate and excessive amounts of vitamin D can lead to serious health problems. Supplementation with 800-1000 IU of vitamin D prevents deficiency and should be monitored to avoid overdose.

Automated summary

A study was conducted to assess the effectiveness of monitored vitamin D supplementation in preterm infants. Results showed that a higher percentage of infants in the monitored group had safe vitamin D levels, while potential vitamin D toxicity was observed in the standard treatment group. Therefore, vitamin D intake should be between 800-1000 IU and monitored to avoid overdose.